jquants-mcp¶
Talk through Japanese stocks with Claude — backed by the J-Quants API v2.
jquants-mcp is a Japanese-equities-focused MCP (Model Context Protocol) server. It gives Claude — Desktop, CLI, or mobile — 47 specialist tools and a local SQLite cache, turning it into a hands-on companion for your stock research rather than a one-off query tool.
What you can ask Claude¶
Once jquants-mcp is connected, conversational queries like these just work:
- "Sector performance ranking today" — sector-by-sector advance/decline
- "Kioxia (285A) — 3-month candlestick chart" — split-adjusted with SMA overlays
- "Q4 earnings digest for the five major trading houses" — pulls the latest fins_summary rows for each
- "Stocks hitting new year-to-date highs" —
detect_ytd_high_lowscreener - "What's the code for SoftBank?" — reverse-lookup via
search_equities - "Compare TOPIX vs Nikkei 225 over 1 year" — multi-stock comparison chart
Why this exists¶
J-Quants provides institutional-quality Japanese equities data, but drilling into a single stock through the raw API gets repetitive fast — the same code fetched again and again (per-stock pagination, 5–500 req/min plan caps, unfamiliar JSON field names, etc.). So jquants-mcp:
- Caches everything locally so repeat queries are instant.
- Adapts to your J-Quants plan automatically (Free / Light / Standard / Premium).
- Exposes high-level tools that Claude can compose ("show me top movers and draw the chart for the leader") rather than forcing it through low-level endpoint calls.
Get started¶
- Quickstart → — install, register your API key, and have Claude answer your first stock question in 5 minutes.
- Tools → — the user-facing tour of what jquants-mcp can do.
- FAQ → — plan recommendations, common errors, and tips.
For the full technical reference (config schema, deployment shapes, multi-user mode, OAuth setup, every tool with parameter tables), see the README on GitHub.
Not investment advice
This software is a data-access tool, not a financial advisory service. Investment decisions are made at your own risk. See the full disclaimer for details.